Highlander Capital Management’s Standard BioTools LAB Stock Holding History

Highlander Capital Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-3,500	Closed	-$28K	–	782
2016 Q3	$28K	Sell	3,500 -1,000	-22%	-$9.18K	0.03%	457
2016 Q2	$41K	Hold	4,500	–	–	0.04%	391
2016 Q1	$36K	Sell	4,500 -1,500	-25%	-$10.8K	0.03%	415
2015 Q4	$65K	Sell	6,000 -2,000	-25%	-$19.6K	0.06%	306
2015 Q3	$64K	Sell	8,000 -500	-6%	-$7.87K	0.06%	313
2015 Q2	$206K	Buy	+8,500	New	+$268K	0.18%	142

Other funds holding LAB

LCS

Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Highlander Capital Management's LAB Position: Q4 2016 in Review

Highlander Capital Management sold out of Standard BioTools (LAB) in Q4 2016, closing a stake of 3,500 shares — an estimated $28K sold.

Highlander Capital Management first reported a position in LAB in Q2 2015 and held it in 6 quarters. The position peaked at $206K in Q2 2015. 83 funds tracked by Wall St. Rank hold LAB as of Q4 2016.

Highlander Capital Management reported no remaining Standard BioTools position as of Q4 2016 after selling out during the quarter.
Highlander Capital Management sold 3,500 Standard BioTools shares in Q4 2016, an estimated $28K.
Highlander Capital Management first reported a position in Standard BioTools in Q2 2015 and held it in 6 quarters.
Highlander Capital Management's Standard BioTools position peaked at $206K in Q2 2015.
83 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2016.

Based on Highlander Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.